Beta Bionics CPO sells 4,375 shares for taxes

Beta Bionics’ Chief Product Officer sold shares primarily to cover taxes from RSU vesting while retaining a substantial direct holding.

Rhea-AI Filing Summary

Beta Bionics, Inc. (BBNX) reported that Chief Product Officer Mike Mensinger sold 4,375 shares of common stock on September 2, 2026, in an open-market or private transaction. According to the company’s disclosure, these shares were sold to cover tax withholding obligations related to vesting restricted stock units, and Mensinger held 180,040 shares directly after the sale.

Insider Trade Summary

Net Seller: 4,375 shares

Net Sell 1 txn

Insider Mensinger Mike

Role Chief Product Officer

Sold 4,375 shs ($84K)

Type	Security	Shares	Price	Value
Sale	Common Stock F1, F2	4,375	$19.1131	$84K

Holdings After Transaction: Common Stock — 180,040 shares (Direct)

Footnotes (2)

1. F1. The shares were sold to cover tax withholding obligations associated with the vesting of restricted stock units.
2. F2. The weighted average sale price for the transaction reported was $19.1131 and the range of prices were between $18.89 and $19.545. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided.

Key Figures

Shares sold: 4,375 shares Weighted average sale price: $19.1131 per share Sale price range: $18.89 to $19.545 per share +1 more

4 metrics

Shares sold 4,375 shares Common stock sold on September 2, 2026 to cover tax withholding

Weighted average sale price $19.1131 per share Average price for the reported sale transaction

Sale price range $18.89 to $19.545 per share Range of prices for shares sold in the transaction

Shares held after transaction 180,040 shares Direct common stock holdings of Mike Mensinger after the sale

Key Terms

restricted stock units, weighted average sale price, tax withholding obligations

3 terms

restricted stock units financial

"tax withholding obligations associated with the vesting of restricted stock units"

Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.

weighted average sale price financial

"The weighted average sale price for the transaction reported was $19.1131"

tax withholding obligations financial

"sold to cover tax withholding obligations associated with the vesting"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did Beta Bionics (BBNX) report for Mike Mensinger?

Beta Bionics reported that Chief Product Officer Mike Mensinger sold 4,375 shares of common stock on September 2, 2026, in an open-market or private transaction, and held 180,040 shares directly after the sale.

Why did the BBNX insider sell 4,375 shares?

The company states the 4,375 shares were sold to cover tax withholding obligations associated with the vesting of restricted stock units, indicating the transaction was linked to equity compensation rather than a discretionary portfolio sale.

What price did the BBNX shares sell for in this insider transaction?

The filing reports a weighted average sale price of $19.1131 per share, with individual sale prices ranging between $18.89 and $19.545. Detailed breakdowns by price level are available upon request to the company, the SEC staff, or any security holder.

How many Beta Bionics (BBNX) shares does Mike Mensinger hold after this sale?

After the sale of 4,375 shares, Mike Mensinger directly held 180,040 shares of Beta Bionics common stock, as reported in the filing. The transaction did not involve any derivative securities positions in this report.

Was this BBNX insider sale under a Rule 10b5-1 trading plan?

The filing’s Rule 10b5-1 checkbox is not marked as affirming a trading plan, and the footnotes do not state that the sale was made under a Rule 10b5-1 plan. The filing instead links the sale to tax withholding obligations from RSU vesting.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 09/03/2026 - 06:18 PM EDT Accepted by SEC EDGAR 09/03/2026 - 06:15 PM EDT Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Mensinger Mike

(Last) (First) (Middle)

C/O BETA BIONICS, INC.

11 HUGHES

(Street)

IRVINE CALIFORNIA 92618

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Beta Bionics, Inc. [ BBNX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Product Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
09/02/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	09/02/2026		S(1)		4,375	D	$19.1131(2)	180,040	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The shares were sold to cover tax withholding obligations associated with the vesting of restricted stock units.

2. The weighted average sale price for the transaction reported was $19.1131 and the range of prices were between $18.89 and $19.545. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided.

	/s/ Stephen Feider, Attorney-in-Fact	09/03/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)